
    
      Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety,
      tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels
      (1 mg and 2 mg) of GB-102 on subjects with Diabetic Macular Edema and Retinal Vein Occlusion
      who have received prior treatment with anti-vascular endothelial growth factor (VEGF)
    
  